Xylem SVP sells shares, exercises stock options
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported an open-market sale and an option exercise involving the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported an open-market sale and an option exercise involving the company’s common stock. She sold 4,269 shares at a weighted average price of $117.46 per share, with individual trades ranging from $117.42 to $118.17.
On the same date, she exercised stock options to acquire 3,147 shares of common stock at an exercise price of $86.76 per share, fully exhausting that option grant. After these transactions, she directly owns 3,605 shares of Xylem common stock.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
McShane Geri-Michelle
Role
SVP, CAO
Sold
4,269 shs ($501K)
Approx. gross sale proceeds
$501K
Approx. exercise cost
$273K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,147 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,147 | $86.76 | $273K |
| Sale | Common Stock | 4,269 | $117.46 | $501K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 3,605 shares (Direct)
Footnotes (2)
- F1. This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 4,269 Shares were executed at a range of prices from $117.42 to $118.17. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
- F2. The March 1, 2022 option grant vested 1,049 options on March 1, 2023, 1,049 options on March 1, 2024, and 1,049 options on March 1, 2025.
Key Figures
Shares sold: 4,269 shares
Sale price (weighted average): $117.46/share
Shares from option exercise: 3,147 shares
+3 more
6 metrics
Shares sold
4,269 shares
Open-market sale of Xylem common stock
Sale price (weighted average)
$117.46/share
Weighted average sale price, range $117.42–$118.17
Shares from option exercise
3,147 shares
Common shares acquired via option exercise
Option exercise price
$86.76/share
Exercise or conversion price of stock options
Shares owned after transactions
3,605 shares
Direct Xylem common stock holdings post-transaction
Options exercised from grant
3,147 options
March 1, 2022 grant fully exercised for these shares
Key Terms
weighted average price, Stock Option (Right to Buy), derivative security, open-market sale, +2 more
6 terms
weighted average price financial
"This price represents the weighted average price per share of common stock"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
exercise price financial
"conversion_or_exercise_price": "86.7600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"option grant vested 1,049 options on March 1, 2023"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Xylem (XYL) SVP Geri-Michelle McShane report?
Geri-Michelle McShane reported selling 4,269 Xylem shares in open-market trades and exercising stock options for 3,147 shares. These moves adjusted her direct holdings while also converting previously granted options into common stock.
What stock options did the Xylem (XYL) SVP exercise in this Form 4?
She exercised stock options covering 3,147 Xylem common shares at an exercise price of $86.76 per share. These options were from a March 1, 2022 grant that vested in three equal annual installments through March 1, 2025.
Were the Xylem (XYL) insider sales executed at a single price or multiple prices?
The 4,269 Xylem shares were sold at multiple prices within a narrow range. The weighted average sale price was $117.46 per share, with actual trade prices ranging from $117.42 to $118.17.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates